Understand the source comparison
Peptides for Acid Reflux Protocol Evidence Guide: Clinical Comparison
Proton-Pump Inhibitors (PPIs) Inhibit H+/K+-ATPase pumps, reducing gastric acid secretion by 80–95% Symptom relief in 2–5 days; mucosal healing in 4–8 weeks High. Multiple Phase III trials, FDA-approved for erosive esophagitis Gold standard for acid suppressio
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- Proton-Pump Inhibitors (PPIs)
- Inhibit H+/K+-ATPase pumps, reducing gastric acid secretion by 80–95%
- Symptom relief in 2–5 days; mucosal healing in 4–8 weeks
- High. Multiple Phase III trials, FDA-approved for erosive esophagitis
- Gold standard for acid suppression, but doesn't repair tissue or prevent recurrence after discontinuation
- BPC-157 (research peptide)
- Upregulates VEGF and NO pathways, accelerates angiogenesis and collagen deposition at injury sites
- Tissue repair observable at 7–14 days in animal models
- Moderate. Robust preclinical data, no human RCTs for GERD
- Strongest mucosal-repair evidence among peptides, but human dosing and safety unvalidated
- KPV (alpha-MSH fragment)
- Inhibits NF-κB translocation, reduces inflammatory cytokine production (TNF-α, IL-6)
- Anti-inflammatory effects within 3–5 days based on IBD data
- Moderate. Phase I IBD trial showed efficacy; no esophageal-specific trials
- Proven anti-inflammatory mechanism, but oral bioavailability is poor. Subcutaneous may be required
- H2 Receptor Antagonists
- Block histamine-mediated acid secretion, less potent than PPIs (50–70% acid reduction)
- Symptom relief in 1–3 days; partial mucosal healing in 6–8 weeks
- High. Extensively studied, FDA-approved for mild-moderate GERD
- Weaker than PPIs for erosive disease; tachyphylaxis (tolerance) develops within 2 weeks of continuous use